Triple-action diabetes jab shown to reduce blood sugar and body weight
A phase 3 trial found that retatrutide, a new weekly injection for type 2 diabetes, significantly lowers blood sugar and body weight by targeting three gut hormones involved in appetite, metabolism, and blood sugar regulation. Participants lost up to 15% of their body weight and saw greater reductions in HbA1c levels compared to those on a placebo. The drug also improved cholesterol and blood pressure, with most side effects being mild and temporary. The results suggest retatrutide could offer a more effective treatment option for people with diabetes and obesity.
A new weekly diabetes jab called retatrutide has been shown to significantly lower blood sugar and body weight in people with type 2 diabetes.
This drug works by targeting three gut hormones, offering a more comprehensive approach to managing diabetes and obesity than existing treatments.
The results provide hope for more effective, long-term treatments that could improve health outcomes and quality of life for people with diabetes and obesity.
upbeatBytes summarizes in its own words and links to the original publisher — it doesn't host the article.